Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 32Triple Negative Breast Neoplasms 26Carcinoma, Transitional Cell 9Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 8Urinary Bladder Neoplasms 7Lung Neoplasms 4Endometrial Neoplasms 3Brain Neoplasms 3Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Fulvestrant 3Letrozole 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1ribociclib 1pegfilgrastim 1exemestane 1abemaciclib 1Zoledronic Acid 1Tamoxifen 1Paclitaxel 1Neoadjuvant Therapy 1Gemcitabine 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Cancer Metastatic × sacituzumab govitecan × 1 year × Clear all
NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Samsung Medical Center

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡